Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach
Acute myeloid leukemia (AML), a hematologic malignancy, is an important public health issue. It is a result of the abnormal proliferation of immature myeloid cells. Despite advancements in diagnostic procedures, the early identification of AML remains a significant clinical challenge, marking a dist...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1601453/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839607473642668032 |
|---|---|
| author | Yiwen Chen Qinhang Li Shifeng Lou Hanqing Zeng Shu Chen |
| author_facet | Yiwen Chen Qinhang Li Shifeng Lou Hanqing Zeng Shu Chen |
| author_sort | Yiwen Chen |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML), a hematologic malignancy, is an important public health issue. It is a result of the abnormal proliferation of immature myeloid cells. Despite advancements in diagnostic procedures, the early identification of AML remains a significant clinical challenge, marking a distinctive niche for newer theranostic approaches to ameliorate diagnosis and treatment. Aptamers are single-stranded oligonucleotides capable of specific binding with high target affinity that have emerged as a promising candidate for molecular recognition in diagnostics and targeted therapy. In this study, we aimed to select and characterize a high-affinity aptamer for C-type lectin-like molecule-1 (CLL-1), an important cell surface marker for AML. CLL-1-specific aptamers were enriched in the context of iterative positive and negative rounds of selection in a systematic evolution of ligands by exponential enrichment (SELEX) approach. In the following, flow cytometry assessment demonstrated the progression of enrichment and then confirmed their performance. The high-throughput sequencing supported the enrichment of five candidate aptamers. In addition, flow cytometry and specificity assays determined that aptamer-2 specifically bound to CLL-1 with an exceedingly high degree of specificity (94.3%) compared with negative controls and other aptamers. The surface plasmon resonance (SPR) valuation revealed that aptamer-2 has a Kd of 1.55 × 10−8 M, which indicates a high affinity of binding to CLL-1. Docking analysis reveals a stable and specific interaction between aptamer-2 and CLL-1, highlighting key binding regions and molecular contacts that may underpin targeted recognition. Taken together, the results put forward aptamer-2 as a highly specific and high-affinity candidate for targeting CLL-1. This study opens the prospect of using this aptamer for diagnostic approaches for AML. Further in vivo and translational studies on its efficacy and efficiency are needed to elucidate its performance in real-world scenarios. |
| format | Article |
| id | doaj-art-9f99b33d3d4c49b881c065c65b571c63 |
| institution | Matheson Library |
| issn | 2296-4185 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj-art-9f99b33d3d4c49b881c065c65b571c632025-08-01T05:31:59ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852025-08-011310.3389/fbioe.2025.16014531601453Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approachYiwen ChenQinhang LiShifeng LouHanqing ZengShu ChenAcute myeloid leukemia (AML), a hematologic malignancy, is an important public health issue. It is a result of the abnormal proliferation of immature myeloid cells. Despite advancements in diagnostic procedures, the early identification of AML remains a significant clinical challenge, marking a distinctive niche for newer theranostic approaches to ameliorate diagnosis and treatment. Aptamers are single-stranded oligonucleotides capable of specific binding with high target affinity that have emerged as a promising candidate for molecular recognition in diagnostics and targeted therapy. In this study, we aimed to select and characterize a high-affinity aptamer for C-type lectin-like molecule-1 (CLL-1), an important cell surface marker for AML. CLL-1-specific aptamers were enriched in the context of iterative positive and negative rounds of selection in a systematic evolution of ligands by exponential enrichment (SELEX) approach. In the following, flow cytometry assessment demonstrated the progression of enrichment and then confirmed their performance. The high-throughput sequencing supported the enrichment of five candidate aptamers. In addition, flow cytometry and specificity assays determined that aptamer-2 specifically bound to CLL-1 with an exceedingly high degree of specificity (94.3%) compared with negative controls and other aptamers. The surface plasmon resonance (SPR) valuation revealed that aptamer-2 has a Kd of 1.55 × 10−8 M, which indicates a high affinity of binding to CLL-1. Docking analysis reveals a stable and specific interaction between aptamer-2 and CLL-1, highlighting key binding regions and molecular contacts that may underpin targeted recognition. Taken together, the results put forward aptamer-2 as a highly specific and high-affinity candidate for targeting CLL-1. This study opens the prospect of using this aptamer for diagnostic approaches for AML. Further in vivo and translational studies on its efficacy and efficiency are needed to elucidate its performance in real-world scenarios.https://www.frontiersin.org/articles/10.3389/fbioe.2025.1601453/fullaptamerC-type lectin-like molecule-1acute myeloid leukemiaSELEXmolecule |
| spellingShingle | Yiwen Chen Qinhang Li Shifeng Lou Hanqing Zeng Shu Chen Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach Frontiers in Bioengineering and Biotechnology aptamer C-type lectin-like molecule-1 acute myeloid leukemia SELEX molecule |
| title | Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach |
| title_full | Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach |
| title_fullStr | Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach |
| title_full_unstemmed | Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach |
| title_short | Design and development of an aptamer targeting C-type lectin-like molecule-1 as a biomarker for acute myeloid leukemia: a SELEX approach |
| title_sort | design and development of an aptamer targeting c type lectin like molecule 1 as a biomarker for acute myeloid leukemia a selex approach |
| topic | aptamer C-type lectin-like molecule-1 acute myeloid leukemia SELEX molecule |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2025.1601453/full |
| work_keys_str_mv | AT yiwenchen designanddevelopmentofanaptamertargetingctypelectinlikemolecule1asabiomarkerforacutemyeloidleukemiaaselexapproach AT qinhangli designanddevelopmentofanaptamertargetingctypelectinlikemolecule1asabiomarkerforacutemyeloidleukemiaaselexapproach AT shifenglou designanddevelopmentofanaptamertargetingctypelectinlikemolecule1asabiomarkerforacutemyeloidleukemiaaselexapproach AT hanqingzeng designanddevelopmentofanaptamertargetingctypelectinlikemolecule1asabiomarkerforacutemyeloidleukemiaaselexapproach AT shuchen designanddevelopmentofanaptamertargetingctypelectinlikemolecule1asabiomarkerforacutemyeloidleukemiaaselexapproach |